U.S. flag An official website of the United States government
  1. Home
  2. Science & Research
  3. FDA Technology Transfer Program
  4. Licensing and Collaboration Opportunities
  5. Solid-phase Purification of Synthetic DNA Sequences
  1. Licensing and Collaboration Opportunities

Solid-phase Purification of Synthetic DNA Sequences

Scientists at the Food and Drug Administration (FDA) have developed a high-throughput method for purifying full-length phosphorothioate and native DNA sequences.  This method comprises a modified silica gel that enables capture of DNA sequences functionalized with a novel linker specifically designed for exclusive capture of full-length sequences.  This technology has been shown to generate DNA sequences of high purity without the need of expensive equipment and associated accessories.  This discovery may improve the availability of pure DNA sequences for clinical and/or synthetic biology applications.

Potential Commercial Applications:

  • A high-throughput purification technique for producing small and large quantities of highly pure DNA sequences.

Competitive Advantages:

  • Cost effective
  • High-throughput capabilities
  • Time-saving
  • High purity

Development Stage:

In Vitro Data Available


Serge L. Beaucage (FDA)
Andrzej Grajkowski (FDA)

Intellectual Property:

PCT/US2017/039720, filed 6/28/17
US Application 16/312,445, filed 12/21/2018


“Solid-Phase Purification of Synthetic DNA Sequences” J. Org. Chem., 2016, 81 (15), pp 6165–6175. PMID: 27382974

Licensing and Collaborative Research Opportunity Contact:

Parties interested in licensing this technology should contact Charlene Maddox at Charlene.Maddox@fda.hhs.gov.

Licensing Contact

Charlene Maddox, Ph.D.
FDA Technology Transfer Program
10903 New Hampshire Ave.
Building WO1, Rm 4214
Silver Spring, MD 20993
Email: FDAInventionlicensing@fda.hhs.gov
Phone: 240-402-4561

FDA Reference No.:



August 15, 2017